Ascletis Reports Preclinical Weight-Loss Data
Ascletis announced preclinical study results for ASC36_35FDC, indicating potential for convenient once-monthly to once-quarterly dosing and significant weight loss. The data was presented at EASD 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.